Opioid-Related Disorders: all 1,439 studies

Page 15 of 15. Open to participants first (291), then studies with results posted, then the rest; newest registration first within each.

• Effects of Subanesthetic Concentrations of Nitrous Oxide - 1CompletedNCT00000249Phase 2
• Effects of Dynorphin 1-13 on Heroin Addiction - 1CompletedNCT00000244Phase 2
• Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on MethadoneTerminatedNCT00000243Not applicable
• Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22CompletedNCT00000240Phase 2
• Buprenorphine Pharmacology Related to Addiction Treatment - 21CompletedNCT00000239Phase 2
• Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20CompletedNCT00000238Phase 2
• Buprenorphine Detoxification - BBDVI - 19CompletedNCT00000237Phase 2
• Buprenorphine Pharmacology Related to Addiction Treatment - 18CompletedNCT00000236Phase 2
• Alternate Day Buprenorphine Administration, Phase XII - 17CompletedNCT00000235Phase 2
• Alternate Day Buprenorphine Administration, Phase XI - 16CompletedNCT00000234Phase 2
• Alternate Day Buprenorphine Administration, Phase X - 15CompletedNCT00000233Phase 2
• Alternate Day Buprenorphine Administration, Phase IX - 14CompletedNCT00000232Phase 2
• Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13CompletedNCT00000231Phase 2
• Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12CompletedNCT00000230Phase 2
• Buprenorphine Detox With Two Types of Treatment. BBD II - 11CompletedNCT00000229Phase 2
• Buprenorphine Detox With Two Types of Treatment. BBD I - 10CompletedNCT00000228Phase 2
• Alternate-Day Buprenorphine Administration. Phase VIII - 9CompletedNCT00000227Phase 2
• Alternate-Day Buprenorphine Administration. Phase VII - 8CompletedNCT00000226Phase 2
• Alternate-Day Buprenorphine Administration. Phase VI - 7CompletedNCT00000225Phase 2
• Alternate-Day Buprenorphine. Phase V - 6CompletedNCT00000224Phase 1
• Alternate-Day Buprenorphine Administration. Phase IV - 5CompletedNCT00000223Phase 2
• Alternate-Day Buprenorphine Administration. Phase II - 4CompletedNCT00000222Phase 1
• Alternate-Day Buprenorphine Administration. Phase I - 3CompletedNCT00000221Phase 1
• Gradual Vs. Rapid Buprenorphine Detoxification - 2CompletedNCT00000220Phase 1
• Buprenorphine Dose Alteration Study - 1CompletedNCT00000219Phase 1
• Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1CompletedNCT00000216Phase 3
• Buprenorphine Dosing Interval - 5CompletedNCT00000209Phase 2
• Methadone/Buprenorphine Cross-Over Study - 4CompletedNCT00000208Phase 2
• Multicenter Clinical Trial of Buprenorphine - 3CompletedNCT00000207Phase 3
• Clinical Rescue Protocol - 2CompletedNCT00000206Phase 2
• Buprenorphine Maintenance Protocol - 1CompletedNCT00000205Phase 3
• Buprenorphine Maintenance for Opioid Addicts - 3CompletedNCT00000204Phase 2
• Buprenorphine Maintenance for Opioid Addicts - 2CompletedNCT00000203Phase 2
• Buprenorphine Maintenance for Opioid Addicts - 1CompletedNCT00000202Phase 2
• Neurobiology of Opioid Dependence: 5 - 5WithdrawnNCT00000196Phase 2
• Neurobiology of Opioid Dependence: 4 - 4WithdrawnNCT00000195Phase 2
• Neurobiology of Opioid Dependence: 3 - 3WithdrawnNCT00000194Phase 2
• Neurobiology of Opioid Dependence: 2 - 2WithdrawnNCT00000193Phase 2
• Neurobiology of Opioid Dependence: 1 - 1WithdrawnNCT00000192Phase 2

← Opioid-Related Disorders overview